- Home
- ITRM vs DXR Comparison
ITRM vs DXR Comparison
Compare ITRM & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ITRM | DXR |
|---|---|---|
| Founded | 2015 | 1970 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 66.3M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | ITRM | DXR |
|---|---|---|
| Price | $0.47 | $12.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $9.00 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 1.3M | 4.3K |
| Earning Date | 11-14-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.46 |
| EPS | N/A | ★ 0.36 |
| Revenue | ★ $390,000.00 | $66,306.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $325.95 | N/A |
| P/E Ratio | ★ N/A | $35.63 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.36 | $6.55 |
| 52 Week High | $3.02 | $14.15 |
Technical Indicators
Market Signals| Indicator | ITRM | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 45.29 | 48.48 |
| Support Level | $0.40 | $12.65 |
| Resistance Level | $0.50 | $13.02 |
| Average True Range (ATR) | 0.06 | 0.45 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 58.91 | 32.94 |
Price Performance
Historical ComparisonAbout ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.